Description: Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Home Page: www.harmonybiosciences.com
HRMY Technical Analysis
630 West Germantown Pike
Plymouth Meeting,
PA
19462
United States
Phone:
484 539 9800
Officers
| Name | Title |
|---|---|
| Mr. Jeffrey S. Aronin | Founder & Non-Exec. Chairman |
| Mr. John Charles Jacobs M.B.A. | Pres, CEO & Director |
| Mr. Sandip S. Kapadia CPA, M.B.A. | Exec. VP & CFO |
| Dr. Jeffrey M. Dayno M.D. | Exec. VP & Chief Medical Officer |
| Mr. Jeffrey Dierks M.B.A. | Exec. VP & Chief Commercial Officer |
| Mr. Andrew Serafin J.D., M.B.A. | Exec. VP & Chief Strategy Officer |
| Mr. David Bradshaw | Head of Technical Operations |
| Ms. Sharon Goldbach | Head of Facilities Operations & Exec. Admin. |
| Luis Sanay | Head of Investor Relations |
| Mr. Christian Ulrich | Gen. Counsel |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 25.641 |
|---|---|
| Trailing PE: | 18.7144 |
| Price-to-Book MRQ: | 10.1167 |
| Price-to-Sales TTM: | 8.308 |
| IPO Date: | 2020-08-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 180 |